Teva Recalls Single Generic Thrombocytopenia Drug Lot

Teva Pharmaceuticals issued a nationwide recall of a single lot of its generic version of Takeda Pharmaceutical’s thrombocytopenia drug Agrylin (anagrelide) because of failed dissolution tests.

The test failure raised concerns about the drug’s effectiveness in reducing platelet counts, which could lead to increased risk of blood clots in patients with thrombocytopenia.

The concerned lot affects 4,224 bottles containing 100 0.5 mg capsules, distributed from July 30 through Sept. 2, 2020.

The voluntary recall was initiated due to dissolution test failures during routine stability testing. The company said no other lots were impacted.